Sitagliptin 100mg + Dapagliflozin 10mg PCD Pharma

Brand Name

SITADOL-D 100/10 Tablet

Composition

Sitagliptin 100mg & Dapagliflozin 10mg

Therapeutic Use

ANTIDIABETICS

Size

10*10

Verified Exporter

Verified Seller

Trusted Pharma

Description

SITADOL-D 100/10 Tablet contains Sitagliptin 100mg + Dapagliflozin 10mg, two oral antidiabetic agents with complementary mechanisms of action. This combination may be prescribed for eligible adults with type 2 diabetes mellitus when a healthcare professional determines that both medicines are appropriate for improving blood glucose control alongside diet, exercise and regular monitoring.


Sitagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The combination works through incretin-hormone regulation and increased urinary glucose excretion. suitability depends on the patient’s clinical condition, kidney function, existing treatment and approved product information.
For procurement teams researching a Sitagliptin 100mg + Dapagliflozin 10mg Tablets manufacturer India, relevant evaluation criteria include composition accuracy, product authorization, manufacturing-source verification, batch traceability and applicable quality documentation.


CardianCare is associated with cardiac and diabetic healthcare products. Businesses searching for a Sitagliptin 100mg + Dapagliflozin 10mg Tablets manufacturer and supplier India can contact the company to confirm product availability, approved specifications and applicable commercial arrangements.


2. Key Ingredient
Composition:

Sitagliptin 100mg + Dapagliflozin 10mg


Sitagliptin 100 mg
Sitagliptin is a DPP-4 inhibitor that helps prolong the activity of incretin hormones. These hormones support glucose-dependent insulin release and help regulate glucagon secretion, contributing to blood glucose control.
Businesses evaluating a Sitagliptin 100mg + Dapagliflozin 10mg pharmaceutical company India should check the product’s approved composition, labelling, regulatory status and quality documentation before procurement.
Dapagliflozin 10 mg
Dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, allowing more glucose to be eliminated through urine. Its suitability depends on kidney function, the intended indication and the approved prescribing information.
For organizations researching a Sitagliptin 100mg + Dapagliflozin 10mg medicine manufacturer India, verification should include the actual manufacturing source, applicable licences, batch-release documentation, storage requirements and product-specific regulatory compliance.

3. Key Benefits
Potential clinical roles of this combination, when prescribed appropriately, include:
1. Blood glucose management: Combines two distinct mechanisms to support glycaemic control in eligible adults with type 2 diabetes.
2. Complementary pharmacological action: Sitagliptin supports incretin-mediated glucose regulation, while dapagliflozin promotes urinary glucose excretion.
3. Oral dosage form: Provides an oral treatment option for patients for whom the combination is prescribed.
4. Treatment-plan flexibility: May be considered when a clinician determines that both active ingredients are suitable for the patient’s diabetes management plan.
5. Support for individualized care: Can form part of a broader approach that includes diet, physical activity and glucose monitoring.
6. Clinician-directed treatment: Allows healthcare professionals to assess two complementary pathways when selecting appropriate therapy.
The response varies between patients. This combination is not suitable for everyone, and benefits must be weighed against contraindications, adverse effects and individual clinical needs.
Pharmaceutical buyers looking for a Sitagliptin 100mg + Dapagliflozin 10mg supplier India should confirm genuine product availability, product authorization, shelf life, packaging details and supply terms.
An enquiry involving a Sitagliptin 100mg + Dapagliflozin 10mg Tablet wholesaler and distributor India should address applicable licences, procurement documentation, batch traceability, storage conditions and distribution eligibility.
Businesses considering a Sitagliptin 100mg + Dapagliflozin 10mg bulk supplier India can request information on available pack sizes, minimum order quantities, batch documentation and commercial quotations, subject to confirmation by the company.
A Sitagliptin 100mg + Dapagliflozin 10mg pharmaceutical distributor India enquiry should include verification of product availability, distribution authorization and applicable local regulatory requirements.

4. How Does It Work?
The two active ingredients act through different pathways:
– Sitagliptin: Inhibits the DPP-4 enzyme, slowing the breakdown of incretin hormones. This supports glucose-dependent insulin secretion and helps regulate glucagon levels.
– Dapagliflozin: Inhibits the SGLT2 transporter in the kidneys, reducing glucose reabsorption and increasing glucose excretion through urine.
Together, these mechanisms may support blood glucose control in suitable adults with type 2 diabetes. They do not replace dietary management, physical activity, regular monitoring or medical follow-up. The appropriateness of this combination must be assessed by the prescribing clinician.

5. Directions for Use
– Dosage: Use only as prescribed by a qualified doctor. Do not independently change the dose.
– Administration: Follow the approved product label and the healthcare professional’s instructions regarding administration and food.
– Regular timing: Take the medicine consistently according to the prescribed schedule.
– Kidney function: Kidney function should be assessed before treatment and monitored when clinically indicated. Dapagliflozin’s suitability and the treatment plan depend on renal status.
– Missed dose: Follow the patient information leaflet or ask a doctor or pharmacist. Do not take an extra dose to compensate without appropriate instructions.
– Lifestyle measures: Continue the recommended diet, exercise and blood glucose monitoring plan.
– Treatment changes: Do not stop, combine or substitute diabetes medicines without medical advice.
Do not assume that a dose suitable for one patient is appropriate for another. Always follow the locally approved product information.

6. Possible Side Effects
Possible adverse effects associated with the active ingredients may include:
– Genital fungal infections
– Urinary tract infections or urinary symptoms
– Increased urination
– Headache or upper respiratory symptoms
– Dizziness or symptoms associated with dehydration
– Low blood glucose, particularly when used with insulin or sulfonylureas
Important warning signs
– Possible ketoacidosis: Nausea, vomiting, abdominal pain, unusual tiredness or difficulty breathing require urgent medical assessment. Ketoacidosis can occur even when blood glucose is not markedly elevated.
– Severe urinary or genital infection: Fever, severe pain or worsening urinary or genital symptoms need prompt assessment.
– Dehydration or low blood pressure: Marked dizziness, fainting or reduced fluid intake should be discussed promptly with a healthcare professional.
– Allergic reaction: Facial or throat swelling, breathing difficulty or a severe allergic reaction requires emergency care.
This is not a complete list of adverse effects. Refer to the approved product information and seek professional advice about any persistent or concerning symptoms. Official dapagliflozin prescribing information highlights ketoacidosis, volume depletion and genitourinary infections as important precautions.

7. Safety Information
– Medical supervision: Use only under qualified medical supervision.
– Allergies: Do not use if there is a known serious allergy to either active ingredient or an excipient in the product.
– Kidney function: Assess renal function before treatment and during therapy as clinically appropriate. The suitability of dapagliflozin depends on the indication and renal status.
– Ketoacidosis risk: Inform the doctor about previous ketoacidosis, acute illness, prolonged fasting, planned surgery or other factors that may increase risk. Follow the clinician’s instructions about temporary interruption when indicated.
– Fluid balance: Patients who are older, have low blood pressure, have impaired kidney function or take diuretics may require particular assessment for dehydration and volume depletion.
– Urinary and genital infections: Report symptoms promptly, particularly if severe or recurrent.
– Hypoglycaemia: The risk may increase when the combination is used with insulin or sulfonylureas. A clinician may need to review the overall treatment regimen.
– Pregnancy and breastfeeding: Seek medical advice before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should select an appropriate treatment.
– Other medicines: Tell the doctor about all prescription medicines, over-the-counter products and supplements.
– Storage: Store in the original packaging according to the approved label, protected from excessive heat and moisture and kept out of reach of children.
The above precautions are general information and do not replace the approved prescribing information for the exact product.

8. B2B Pharmaceutical Business Enquiries
CardianCare’s cardiac and diabetic healthcare portfolio is relevant to pharmaceutical professionals researching antidiabetic products. All product availability, commercial terms and business services should be confirmed directly with the company.
For a Sitagliptin 100mg + Dapagliflozin 10mg PCD pharma franchise India enquiry, prospective business partners can ask about eligible products, territory availability, partner criteria and applicable commercial terms. Confirm that the relevant programme is currently offered before making business commitments.
Companies researching Sitagliptin 100mg + Dapagliflozin 10mg Tablets PCD pharma franchise opportunities should request confirmation of product availability, distribution eligibility, promotional policies and required documentation.
A Sitagliptin 100mg + Dapagliflozin 10mg Tablet PCD franchise enquiry should include details about territory terms, applicable licences, order requirements and the exact products covered by any available programme.
Businesses exploring Sitagliptin 100mg + Dapagliflozin 10mgthird party manufacturing India should first confirm whether the company offers this service. Important checks include manufacturing authorization, product approvals, applicable GMP compliance, batch size, quality agreements and regulatory responsibilities.
A Sitagliptin 100mg + Dapagliflozin 10mg Tablet third party manufacturer India search should lead to verification of the actual manufacturing facility, product-specific permissions, technical documentation, quality controls and batch-release procedures.
Companies investigating Sitagliptin 100mg + Dapagliflozin 10mg contract manufacturing India should confirm the proposed partner’s capabilities, regulatory permissions, formulation specifications, packaging requirements, quality responsibilities and contractual terms.
Contact CardianCare through its official website to enquire about the product, current availability and applicable pharmaceutical business opportunities. Manufacturer, supplier, franchise and manufacturing-service arrangements must be verified directly before being represented as available.

For more information about SITADOL-D 100/10 Tablet (Sitagliptin 100mg + Dapagliflozin 10mg), Click Here

Frequently Asked Questions

It may be prescribed for blood glucose management in eligible adults with type 2 diabetes mellitus when a clinician considers both active ingredients appropriate.

The stated composition is Sitagliptin 100 mg and Dapagliflozin 10 mg. Confirm these strengths against the approved product label before publication or dispensing.

Sitagliptin inhibits the DPP-4 enzyme to support incretin-mediated glucose regulation. Dapagliflozin inhibits SGLT2 in the kidneys to increase glucose excretion through urine.

The combination provides two complementary mechanisms of blood glucose control in suitable patients. Its overall benefit depends on individual clinical needs, renal function and the prescribed treatment plan.

Take it only as prescribed by a doctor and follow the approved product label. Do not adjust the dose or change the treatment schedule without medical advice.

Possible effects include genital fungal infections, urinary tract infections, increased urination, headache, dizziness and dehydration. Seek urgent medical care if symptoms suggest ketoacidosis or a severe allergic reaction.

Patients with kidney problems, low blood pressure, recurrent urinary or genital infections, previous ketoacidosis, pregnancy or breastfeeding considerations, or relevant allergies should discuss treatment suitability with their clinician.

A clinician may prescribe combination therapy when appropriate. Using it with insulin or sulfonylureas can increase hypoglycaemia risk, so the full treatment regimen should be reviewed by a healthcare professional.

Buyers should verify the active ingredients and strengths, approved product status, actual manufacturing source, applicable licences, batch documentation, packaging, storage conditions, shelf life and commercial terms.

Contact CardianCare through its official website to confirm product availability and ask about applicable business arrangements. Any distribution, franchise or manufacturing service should be confirmed directly."

Reviews

There are no reviews yet.

Be the first to review “Sitagliptin 100mg + Dapagliflozin 10mg PCD Pharma”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line